Wegovy is approved as a long-term medication, and most people will need to stay on it indefinitely to maintain their weight loss. The FDA labels it for “long-term” weight reduction and maintenance, and major obesity medicine organizations classify obesity as a chronic disease requiring ongoing treatment. There is no set end date built into the prescribing guidelines.
That said, “indefinitely” is not what most people want to hear. Here’s what the evidence actually shows about what happens when you stop, how long the ramp-up takes, and whether any strategies can help if you do want to come off it.
What Happens When You Stop
The clearest data comes from a large clinical trial (STEP 4) that took people who had been losing weight on semaglutide for 20 weeks and switched half of them to a placebo. Over the next year, the placebo group regained an average of 6.9% of their body weight, while those who stayed on the medication lost an additional 7.9%. That’s a nearly 15 percentage point gap.
A 2025 systematic review in The BMJ looked across multiple studies and found that people regain weight at an average rate of about 0.4 kg (roughly 1 pound) per month after stopping. For those who had been on newer drugs like semaglutide specifically, the projected timeline to return to their original pre-treatment weight was approximately 1.5 years. Cardiometabolic improvements in things like blood sugar, cholesterol, and blood pressure followed a similar pattern, returning to baseline within about 1.4 years.
This isn’t a willpower problem. These medications work by mimicking a hormone that regulates appetite signals in the brain. When the drug is removed, those signals revert to their previous state. The underlying biology that drove weight gain in the first place hasn’t changed.
The First 16 Weeks: Dose Escalation
Before you even reach the full maintenance dose, Wegovy requires a 16-week titration schedule. You start at a low dose and increase every four weeks to give your body time to adjust and reduce side effects, particularly nausea:
- Weeks 1 through 4: 0.25 mg
- Weeks 5 through 8: 0.5 mg
- Weeks 9 through 12: 1 mg
- Weeks 13 through 16: 1.7 mg
- Week 17 onward: 1.7 mg or 2.4 mg maintenance dose
Most weight loss occurs during and after this escalation period. The maintenance dose is where you’ll stay for the long haul. Some people tolerate 1.7 mg well enough that their prescriber keeps them there rather than pushing to 2.4 mg.
Can You Taper Off Instead of Stopping Cold?
Some clinicians have experimented with gradually reducing the dose rather than stopping abruptly. In one study presented at a medical conference, 353 patients tapered their semaglutide over a median of 9 weeks. During the taper itself, they actually lost an additional 2.1% of body weight on average. Among the 85 patients who stopped completely and had follow-up data, weight remained stable for the first 26 weeks.
That sounds promising, but the researchers who conducted the study added an important caveat: at some point, typically within 3 to 18 months, all patients began regaining weight. Many needed to restart treatment. A slow taper may buy time and soften the transition, but it doesn’t appear to be a permanent off-ramp for most people.
Can Lifestyle Changes Replace the Medication?
This is the question most people are really asking. If you build strong exercise and eating habits while on Wegovy, can those habits hold the line after you stop? The BMJ review examined this directly and found no evidence that behavioral support, whether provided during treatment or after stopping, changed the rate of weight regain. People who had intensive coaching regained weight at the same pace as those who had minimal support, once the drug was removed.
That doesn’t mean healthy habits are pointless. Exercise, sleep, and nutrition all matter for overall health regardless of your weight. But the data suggests these habits alone can’t replicate what the medication does to appetite regulation. The biological drive to regain weight operates below the level of conscious decision-making.
Long-Term Safety Over Several Years
If staying on Wegovy long-term is the expectation, safety data matters. The largest and longest study to date, the SELECT trial, followed patients for nearly four years on average. Serious adverse events were actually lower in the semaglutide group than in the placebo group (33.4% vs. 36.4%), driven largely by fewer cardiac events.
The main downside was gastrointestinal side effects. About 16.6% of semaglutide patients discontinued due to adverse events, compared to 8.2% on placebo, with GI issues (nausea, vomiting, diarrhea) accounting for most of that difference. Gallstone-related problems were slightly more common (2.8% vs. 2.3%). Rates of pancreatitis, kidney problems, cancer, and psychiatric events were similar between the two groups. Concerns about suicidal thoughts were not supported: rates were identical at 0.11% in both groups.
For most people who tolerate the medication well through the first several months, the long-term safety profile appears reassuring based on available data.
Insurance and Renewal Requirements
Even if you plan to stay on Wegovy long-term, your insurance may require periodic reauthorization. Approval structures vary by plan, but a common pattern is initial authorization for six months, followed by renewals in six-month increments. Renewals typically require that you still meet the original prescribing criteria for the medication.
This means you may need regular check-ins with your prescriber to document continued medical necessity. If your insurance requires a minimum weight loss threshold to approve continuation, losing coverage of the drug could force an unplanned stop, so it’s worth understanding your plan’s specific criteria early on.
The Realistic Picture
The honest answer to “how long do you have to stay on Wegovy” is that the medication works for as long as you take it, and the weight returns when you stop. Current medical guidelines treat it the same way they treat blood pressure or cholesterol medication: as ongoing management of a chronic condition, not a temporary fix. Some people may eventually try tapering to a lower maintenance dose or cycling on and off the drug, but these strategies don’t yet have strong evidence behind them. For now, the expectation set by both the FDA labeling and clinical experience is that Wegovy is a long-term commitment.